Suppr超能文献

硝苯地平、维拉帕米和地尔硫䓬对猫肺血管阻力及血管收缩剂的影响。

Influence of nifedipine, verapamil and diltiazem on pulmonary vascular resistance and vasoconstrictors in cats.

作者信息

Erdemli O, Hao Q, Cai B, Lippton H L, Hyman A

机构信息

Department of Surgery, Tulane University Medical Center, New Orleans, LA 70112, USA.

出版信息

Arch Int Pharmacodyn Ther. 1994 Sep-Oct;328(2):165-79.

PMID:7535994
Abstract

In the present study, the effects of three classes of L-type calcium channel-blocking agents, nifedipine, verapamil and diltiazem, on the lobar arterial pressure and the vasoconstrictor responses in the pulmonary vascular bed were compared to those of cromakalim, a KATP channel activator, in the anaesthetized cat under controlled pulmonary blood flow and constant left atrial pressure. These drugs were infused intralobarly in doses selected which did not raise left atrial pressure, change cardiac output or alter systemic arterial pressure. Intralobar bolus injections of calcium channel-blocking agents and of the K+ channel activator decreased the lobar arterial pressure in a dose-related manner when pulmonary vasomotor tone was actively elevated by intralobar arterial infusion of U46619. The pulmonary vasodilator response to these agents was accompanied by a dose-related decrease of systemic arterial pressure. In decreasing lobar arterial pressure at elevated pulmonary vasomotor tone, the order of potency was nifedipine > verapamil > diltiazem, whereas in reducing systemic arterial pressure, the order of potency was nifedipine > diltiazem > verapamil. The calcium channel-blocking agents were less active than the reference drug, cromakalim, in both vascular beds. Intralobar arterial infusions of nifedipine, verapamil and diltiazem, at the rates of 0.03 mumol/min, 0.2 mumol/min and 0.1 mumol/min, respectively, caused no changes in cardiac output and in systemic and pulmonary arterial pressure. Infusion of all three calcium-channel-blocking agents blocked the pulmonary vasoconstrictor responses to BAY K 8644 (calcium entry promoter) and U46619 (thromboxane A2 mimic). Nifedipine infusion also reduced the pulmonary vasoconstrictor responses to methoxamine and BHT933 (alpha 1- and alpha 2-adrenoceptor agonists, respectively), whereas verapamil infusion reduced the responses only to methoxamine. Infusion of diltiazem caused no significant decrease of responses to either alpha-adrenoceptor agonist. The results of the present study suggest that the dihydropyridine, nifedipine, is more potent than the non-dihydropyridines, verapamil and diltiazem, in reducing the pulmonary vascular resistance and more effective in inhibiting the vasoconstrictor responses to the alpha-adrenoceptor agonists, to U46619 and to BAY K 8644 in the feline pulmonary circulation at the infusion rates which cause no or little hemodynamic changes.

摘要

在本研究中,在肺血流量受控且左心房压力恒定的麻醉猫身上,比较了三类L型钙通道阻滞剂硝苯地平、维拉帕米和地尔硫䓬对叶动脉压和肺血管床血管收缩反应的影响,与钾通道开放剂克罗卡林的影响进行对比。这些药物以选定的剂量进行叶内输注,这些剂量不会升高左心房压力、改变心输出量或改变体动脉压。当通过叶内动脉输注U46619使肺血管运动张力主动升高时,叶内推注钙通道阻滞剂和钾通道开放剂会以剂量相关的方式降低叶动脉压。这些药物的肺血管舒张反应伴随着体动脉压的剂量相关下降。在肺血管运动张力升高时降低叶动脉压方面,效力顺序为硝苯地平>维拉帕米>地尔硫䓬,而在降低体动脉压方面,效力顺序为硝苯地平>地尔硫䓬>维拉帕米。在两个血管床中,钙通道阻滞剂的活性均低于参比药物克罗卡林。分别以0.03 μmol/min、0.2 μmol/min和0.1 μmol/min的速率进行叶内动脉输注硝苯地平、维拉帕米和地尔硫䓬,不会引起心输出量以及体动脉压和肺动脉压的变化。输注所有三种钙通道阻滞剂均能阻断肺血管对BAY K 8644(钙内流促进剂)和U46619(血栓素A2类似物)的血管收缩反应。输注硝苯地平还能降低肺血管对甲氧明和BHT933(分别为α1和α2肾上腺素能受体激动剂)的血管收缩反应,而输注维拉帕米仅能降低对甲氧明的反应。输注地尔硫䓬对两种α肾上腺素能受体激动剂的反应均未引起显著降低。本研究结果表明,在不引起或仅引起轻微血流动力学变化的输注速率下,二氢吡啶类药物硝苯地平在降低肺血管阻力方面比非二氢吡啶类药物维拉帕米和地尔硫䓬更有效,并且在抑制猫肺循环中对α肾上腺素能受体激动剂、对U46619和对BAY K 8644的血管收缩反应方面更有效。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验